Dr. Fung: ‘Cholesterol is barely relevant to Heart Disease’

<p><strong>*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*</strong>Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 <strong>*HEALTH AUTONOMY [COURSE]*</strong>Learn to Analyze &amp; Apply Studies for Yourself: https://bit.ly/healthautonomy<strong>*JOIN THE COMMUNITY*</strong>Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2<strong>*EMAIL LIST*</strong>1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6<strong>*HIRE ME FOR CONSULTING:* </strong>Consulting: https://bit.ly/3dmUl2H Created with Biorender0:00 - Introduction2:13 - Blood Cholesterol is not Important13:08 - Something else matters WAY more than Blood Cholesterol16:45 - Main PointsReferences[Funding/Conflicts are provided in the free article (found in the email list and Physionic Community Article Library)][1] Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149:430–449. doi:10.1161/CIRCULATIONAHA.123.067626.[2] Dugani SB, Moorthy MV, Li C, et al. Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident coronary heart disease in women. JAMA Cardiol. 2021;6(4):437–447. doi:10.1001/jamacardio.2020.7073.[3] Magnussen C, Alegre-Diaz J, Al-Nasser LA, et al. Global effect of cardiovascular risk factors on lifetime estimates. N Engl J Med. 2025;393(2):125–138. doi:10.1056/NEJMoa2415879.[4] Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e1154–e1276. doi:10.1161/CIR.0000000000001423.[5] Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489.[6] Nordestgaard BG, Langlois MR, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46–61. doi:10.1016/j.atherosclerosis.2019.12.005.[7] Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–1839. doi:10.1016/S0140